Tag: scholz

Quick Search


How To Pick The Best Treatment For Prostate Cancer

Mon 1 Oct 2012

Read the pamphlet text below or click here to download a PDF of this 3-fold pamphlet.   For picking prostate cancer treatment, the most important consideration is quality-of-life. Long term survival is the norm so lingering side effects from treatment are a leading concern. Treatment selection starts by segregating men into Low, Intermediate or High-RiskRead More ›

Diet, Vitamins, and Exercise for Prostate Cancer

Mon 1 Oct 2012

In particular, unhealthy diets encourage prostate cancer growth and spread. The importance of diet can be easily established by looking at mortality rates from prostate cancer in China where the risk of dying is eighteen times lower than in the United States.1 Genetic factors cannot explain these differences since Asians who come to the UnitedRead More ›

Testosterone Inactivating Pharmaceuticals

Tue 30 Nov 2010

By Mark Scholz, M.D., Prostate Oncology Specialists Edited from PCRI Insights November, 2010 v 13.4 For print friendly version, download the PDF for this article Prostate cancer needs testosterone to survive. Blocking testosterone is proven to prolong life in randomized prospective trials. Testosterone Inactivating Pharmaceuticals (TIP), otherwise known as androgen deprivation or hormone blockade, areRead More ›

Anti-androgen Monotherapy

Fri 1 Oct 2010

By: Mark Scholz, M.D. Prostate Oncology Specialists October 2010 Traditionally, anti-androgen medications have been used in combination with LHRH agonists to block testosterone. When anti-androgens are used alone, as so-called anti-androgen monotherapy, it causes in a milder degree of testosterone blockade. There are three anti-androgens—bicalutamide, flutamide, and nilutamide. They work by keeping testosterone away fromRead More ›

Preventing Side Effects from Testosterone Inactivating Pharmaceuticals

Fri 1 Oct 2010

By: Mark Scholz, M.D. Prostate Oncology Specialists October 2010 Testosterone inactivating pharmaceuticals (TIP) prolong survival in randomized prospective trials. TIP, when used after surgery in men with lymph node metastasis, decreases mortality seven fold when used immediately rather than being delayed to the time of disease progression.1 TIP administered with radiation reduces prostate cancer mortality.2Read More ›

Immune Treatment for PSA-Relapsed Prostate Cancer

Fri 1 Oct 2010

By: Mark Scholz, M.D. Prostate Oncology Specialists October 2010 PSA-Relapsed prostate cancer can be effectively controlled with Testosterone Inactivating Pharmaceuticals (TIP). When TIP is started soon after relapse, remissions last an average of 11 years. However, TIP has notable side effects such as low libido, hot flashes, osteoporosis, muscle wasting and weight gain. Quality-of-life isRead More ›

Bisphosphonates for Osteoporosis or Bone Metastasis

Fri 1 Oct 2010

By: Mark Scholz, M.D. Prostate Oncology Specialists October 2010 Bisphosphonates come in oral and intravenous forms. They can be used to treat osteoporosis and/or metastatic cancer in the bones. The oral agents, Fosamax®, Boniva® and Actonel® are primarily for osteoporosis. The intravenous agents, Zometa® and Aredia®, are primarily for cancer, though they are also potentRead More ›

Avodart (dutasteride) & Proscar (finasteride)

Fri 1 Oct 2010

By: Mark Scholz, M.D. Prostate Oncology Specialists October 2010 Avodart® and Proscar® are FDA approved for the treatment of benign prostatic hyperplasia (BPH), the natural enlargement of the prostate that occurs with aging.  They are well-tolerated agents, except for occasional impotence or reduced libido that resolves when the treatment is stopped. Proscar and Avodart workRead More ›

Can Diet Really Control Prostate Cancer?

Thu 23 Feb 2006

Can Diet Really Control Prostate Cancer? Mark Scholz, MD and Ralph Blum Reprinted from PCRI Insights February 2006 vol. 9, no. 1 In December 2001 Thomas Mueller, a Los Angeles attorney, learned he had prostate cancer (PC). Thomas’s disease was the contained variety of PC, but at age 45 and newly married, he was alarmedRead More ›

Laboratory Tests Defined

Tue 31 May 2005

PCRI Insights May, 2005 vol. 8, no. 2 By Mark C. Scholz, MD, Director, Prostate Oncology Specialists, Marina del Rey, CA An important first step in the screening procedure is, of course, the physical examination taken at the first visit of a patient to our practice and scheduled to be repeated each year thereafter. InRead More ›